ImmunityBio, Inc. IBRX Operating Lease Right-of-Use Assets in Other Assets
Operating Lease Right-of-Use Assets in Other Assets at other companies
Other financials
Where this comes from
Reported directly by ImmunityBio, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OperatingLeaseRightOfUseAsset.
The official record: ImmunityBio, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about ImmunityBio, Inc.'s operating lease right-of-use assets in other assets.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ImmunityBio, Inc.'s operating lease right-of-use assets in other assets?
- ImmunityBio, Inc. (IBRX) reported operating lease right-of-use assets in other assets of $33.03M in Q1 2026.
- How has ImmunityBio, Inc.'s operating lease right-of-use assets in other assets changed year-over-year?
- ImmunityBio, Inc.'s operating lease right-of-use assets in other assets increased by 3.9% year-over-year, from $31.78M to $33.03M.
- What is the long-term trend for ImmunityBio, Inc.'s operating lease right-of-use assets in other assets?
- Over 5 years (2020 to 2025), ImmunityBio, Inc.'s operating lease right-of-use assets in other assets has grown at a 12.7% compound annual growth rate (CAGR), from $18.14M to $33.01M.